Issuer/Manager THE TRENDLINES GROUP LTD.

Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T

Stapled Security No

Announcement Title Financial Statements and Related Announcement

Date & Time of Broadcast 10 May 2016 23:46:20

Status New

Announcement Subtitle First Quarter Results

Announcement Reference SG160510OTHR6OQZ

Submitted by (Co./Ind. Name) Yosef Ron

Designation Joint Company Secretary

Description Please see attached press release and Financial Highlights Q1 2016 Presentation.

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.

Attachments Press Release and Financial Highlights Presentation Q1 2016

1

For Immediate Release

Trendlines’ total portfolio value increases to US$86.9 million

• Total income of US$1.1 million for 1Q2016, lower than 1Q2015 primarily due to

change in fair value of investments in Portfolio Companies

• Income from contracted R&D services increased to US$0.3 million from US$0.1

million supported by new collaboration agreements in relation to R&D services

provided by Trendlines Labs

• Net loss of US$0.8 million for 1Q2016

• Multiple achievements in establishing strategic partnerships with renowned

multinational companies year to date, to enhance deal flow and future growth

Singapore, 10 May 2016 – The Trendlines Group Ltd. (the “Company”, and together with its

subsidiaries and associated companies, the “Group”), an Israeli company focused on developing

technology-based companies in the medical and agricultural fields, announced its financial results for

the three months ended 31 March 2016 (“1Q2016”) today.

2

1Q2016 1Q2015 Change

US$'000 US$'000 %

Gain(loss) from change in fair value of

investments in Portfolio Companies (992) 1,202 N.M.

Income from services to portfolio companies 1,281 1,231 4.0

Income from contracted R&D services 330 102 223.2

Total income 1,140 3,160 (63.9)

Total expenses 2,633 2,218 18.7

Net income (loss) and total comprehensive

income (loss) (770) 580 N.M.

*N.M.: Not meaningful

Total income for the Group was US$1.1 million in 1Q2016, compared to US$3.2 million in 1Q2015. The

reduction in total income is primarily attributable to a net loss in the fair value of investments in

portfolio companies of US$1 million, compared to a net gain in 1Q2015 amounting to US$1.2 million.

This net loss in the fair value of portfolio companies in 1Q2016 takes into account an increase of

US$3.9 million in the fair value of the Most Valuable Portfolio Company1, as well as an aggregate fair

value gain of US$0.6 million for some other portfolio companies as a result of the completion of fund

raising exercises at favourable valuations and general commercial and technological progress during

the quarter. However, this gain was offset by an aggregate fair value loss of US$4.8 million, as a result

of the completion of fund raising exercises for some other portfolio companies at less favourable

terms to the Company, as well as general commercial or technological difficulties in some companies

and the write off of two portfolio companies during the quarter in the amount of US$1.0 million.

Income from services to portfolio companies remained relatively unchanged in 1Q2016 as compared

to 1Q2015. Income from contracted R&D services increased to US$0.3 million from US$0.1 million due

to new collaboration agreement in relation to R&D services provided by Trendlines Labs to a third

party.

1 As defined in the Company’s offer document dated 16 November 2015

3

Our loss before taxes was US$1.5 million for the quarter compared to a gain of approximately US$0.9

million in first quarter of 2015.

Income tax for the quarter was a tax benefit of approximately US$0.7, due to the effect of reduction in

the deferred taxes which was caused mainly by the reduction in tax rate from 26.5% to 25%. This

resulted in a net loss for the quarter of US$0.8 million, compared to a profit of US$0.5 million in

1Q2015.

The Group maintained a strong financial position. As at 31 March 2016, the Group had cash and cash

equivalents of US$8.2 million, compared to US$7.0 million as at 31 December 2015. Current assets as

at 31 March 2016 were $21.5 million, as compared to US$24.0 million at the end of 2015. The

reduction in current assets reflects investments in our portfolio companies and current operations

during the first quarter which reduced short term investments to US$12.0 million, from US$16.4

million on 31 December 2015.

The fair value of all the portfolio companies (“portfolio value”), including the fair value of a company

carried at equity value, as at 31 March 2016 was approximately US$86.9 million, compared to US$85.8

million as at 31 December 2015. The increase was primarily attributable to an increase of US$3.9

million in the fair value of the Most Valuable Portfolio Company.

Commenting on the 1Q2016 financial results, Mr. D. Todd Dollinger, Co-Chairman and CEO of the

Group, said, “The nature of our business has two distinct characteristics in our financials as compared

to that of any traditional business. Firstly, the fair value of our portfolio companies changes according

to the progress in their fund raising and technological and commercial development, and the varying

rates of progress at different companies could lead to variations in fair value on a portfolio level from

quarter to quarter. Secondly, as significant monetary gain is generated chiefly by exits from our

portfolio companies, the financial performance and earnings can be volatile.

“Trendlines’ value to portfolio companies lies in providing support ranging from technological

development and business development to marketing and fund raising. Our goal is to assist portfolio

companies to achieve a relatively smooth growth path to commercialization, and to eventually exit

from these investments with optimal returns. We are working hard to achieve this goal, and we will

update the market as exit projects materialize.”

4

Mr. Steve Rhodes, Co-Chairman and CEO of the Group, added, “Despite the quarterly numbers, we

made a promising start for 2016. We entered into a definitive collaboration agreement with B. Braun

on establishing mutual deal flow and the development of new technologies; Bayer AG committed

US$10 million in the Bayer Trendlines Agtech Innovation Fund which will focus on making early-stage

agritech investments and will be managed by Trendlines. Separately, Trendlines Labs entered into a

collaboration agreement with a major MNC headquartered in Japan to develop innovative medical

device products for manufacturing and marketing by the Japanese MNC. Trendlines Labs also

received an additional order from a large U.S. medical device company, following its successful

collaboration with the company earlier.

“These partnerships are an endorsement of Trendlines’ business model and our R&D capabilities.

Collaboration with these industry leaders in their respective fields will raise Trendlines’ visibility in the

medical and agricultural technologies space, provide us with a larger platform to improve human

condition, stimulate our growth, and enhance the potential for us to generate long-term value to our

shareholders.”

- The End -

__________________________________________________________________________________

Issued for and on behalf of The Trendlines Group Ltd.

By Financial PR Pte Ltd.

For more information, please contact:

Romil SINGH / Reyna MEI

romil@financialpr.com.sg / reyna@financialpr.com.sg

Tel: (65) 6438 2990, Fax: (65) 6438 0064

__________________________________________________________________________________

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities

Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was

sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor"). This press release has been

prepared by the Company and its contents have been reviewed by the Sponsor for compliance with

5

the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this

press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and

the SGX-ST assume no responsibility for the contents of this press release, including the accuracy,

completeness or correctness of any of the information, statements or opinions made or reports

contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of

Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone

(65) 6229 8088.

Creating & Developing Companies To Improve the Human Condition

Financial Highlights Q1 2016 May 2016

Legal Disclaimer

IMPORTANT NOTICE

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information, or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors, such as known and unknown risks and uncertainties, and assumptions including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statement, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its content may be used without the prior written consent of the Company.

2

I. Overview & Business Model

II. Financial Highlights Balance Sheet Profit & Loss

III. Portfolio Highlights

IV. Q1 2016 Highlights

V. Stock Information

VI. Upcoming Events

Contents

3

I. Overview & Business Model

4

The Trendlines Group invents, discovers, invests in, and incubates life science companies in the fields of medical and agricultural technologies.

Trendlines: Innovation Commercialization

Invest through Israeli Government-Franchised Incubators Invest in life sciences companies

Internal Innovation Center Invents and develops technologies to address unmet market needs

5

Trendlines: Deal Flow to Exit

6

II. Financial Highlights Balance Sheet

Profit & Loss

7

Trendlines: Balance Sheet Summary

31 March 2016 Unaudited

31 Dec 2015 Audited

US$’000 US$’000

ASSETS

Total Current Assets 21,472 24,000

Total Non-Current Assets 85,739 84,988

Total Assets 107,211 108,988

LIABILITIES AND EQUITY

Total Current Liabilities 3,287 3,657

Total Long-Term Liabilities 20,292 21,173

EQUITY

Total 83,598 84,124

Non-Controlling Interests 34 34

Total Equity 83,632 84,158

Total Liabilities and Equity 107,211 108,988

Key Financial Ratios

Current Assets to Current Liabilities 6.53

Total Assets to Total Liabilities 4.55

Price to Book Value* 0.92

Price to Portfolio Value* 0.88

*Based on market value as of close of trading on 6 May 2016 of S$ 104.3 million. Portfolio Value includes value of company reported on equity basis.

8

Trendlines: Profit & Loss Summary

Three months ended: 31 March 2016

Unaudited 31 March 2015

Unaudited

US$’000 US$’000

Total income 1,140 3,160

Total expenses before non-recurring, non-cash expenses related to discount on pre-IPO RCL upon IPO conversion 2,633 2,218

Income/(loss) before income taxes (1,493) 942

Income tax credit/(expense) 723 (362)

Net Income/(loss) and total comprehensive income/loss (770) 580

9

10

III. Portfolio Highlights

Trendlines: Growth of Portfolio Value

0

10000

20000

30000

40000

50000

60000

70000

80000

90000

100000

31.12.07* 31.12.08* 31.12.09* 31.12.10* 31.12.11* 31.12.12 31.12.13 31.12.14 31.12.15 31.3.16**

Portfolio Values US$ 000

FV of investments in consolidated non-operatingsubsidiaries

Fair Value ("FV") of investments in companiesaccounted for under the equity method

Portfolio Value

47,499

74,639 77,494

85,776

* Audited under IFRS but not reported to the public ** Unaudited

29,309 25,486

22,760

16,189

8,517

86,899

11

Trendlines: Building Value Over Time

One of our 10 most valuable portfolio companies as at 31 March 2016.

As at 31 March 2016; 19 written-off portfolio companies and 2 companies established before September 2007 not listed. IPO indicates reverse mergers into public companies.

12

Trendlines: 10 Most Valuable Portfolio Companies

Company Name Initial Investment % Owned

(Fully Diluted)

ApiFix Ltd. 2011 29.42

Arcuro Medical Ltd. 2013 42.59

E.T.View Medical Ltd. 2008 27.86

Leviticus Cardio Ltd. 2010 29.27

Liola Technologies Ltd. 2010 29.14

NeuroQuest Ltd. 2008 30.75

Omeq Medical Ltd. 2013 42.89

Stimatix GI Ltd. 2009 27.17

STS Medical Ltd. 2013 35.37

VivoText Ltd. 2008 26.22

Total estimated fair market value of our 10 most valuable portfolio companies: approximately US$62.2*million, representing 71.6% of total portfolio value of approximately US$86.9*million as at 31 March 2016.

*Including FV of investments in companies accounted for under the equity method in the amount of US$1,700,000

13

14

IV. Q1 2016 Highlights

• Definitive cooperation agreement signed with B. Braun Melsungen AG.

• Trendlines Labs

• Signed framework agreement with large Japanese medtech multinational.

• Received new order from large U.S. medtech multinational.

• Moshe Katzenelson named VP International Incubators.

• Trendlines Company Showcase (27 January) attracted more than 400 attendees.

15

Trendlines: Corporate News Q1 2016

• New Company established: AquiNovo Ltd.

• Significant raises:

• Saturas Ltd. about US$1 million

• Magdent Ltd. about US$800,000

• E.T.View Medical Ltd. reported 2015 sales increased 31% compared to 2014 to NIS 7.74 million

• Trendlines Agtech franchise from OCS not renewed; request submitted to OCS to merge Agtech investment activity into Trendlines Medical.

16

Trendlines: Companies & Incubator News Q1 2016

• Bayer AG signs agreement committing to invest US$10 million in the Bayer Trendlines Ag Innovation Fund.

17

Trendlines: Significant Events Since 31 March 2016

• Arcuro Medical Ltd. raises US$500,000 from Chinese medical device company Naton Medical Group Ltd.

18

V. Stock Information

Trendlines: Stock Overview & Peers

Price to Portfolio (FMV)*

Allied Minds (LSE:ALM) 2.06

Imperial Innovations (AIM:IVO) 1.86

IP Group (LSE:IPO) 1.64

PureTech Health (LSE:PRTC) 1.48

Average Price to Portfolio 1.76

Trendlines Price to Portfolio 0.88

*Based on market cap at 6 May 2016, divided by last available portfolio value Peer Group as identified in DBS Vickers report of 11 Feb 2016

As at 6 May 2016 SGD

Last Price 0.205

IPO Price 0.330

52 Wk High 0.395

52 Wk Low 0.133

Market Cap 104.3 million

Shares Outstanding 508.8 million

Free Float 365.8 million

19

20

VI. Upcoming Events

Trendlines Singapore Medical Company Showcase

8 Companies. 5 Cities. 5 Days.

Singapore, Beijing, Shanghai, Shenzhen, Hong Kong

4-8 July 2016

21

Events Around the World

Showcasing the Israeli agtech ecosystem

Weizmann Institute of Science Rehovot, Israel

27 September 2016

4th ANNUAL

+972.72.260.7000 | www.trendlines.com

Creating & Developing Companies To Improve the Human Condition

Todd Dollinger, Chairman & CEO Steve Rhodes, Chairman & CEO

11 May 2016

Judith Kleinman, Director Investor Relations & Corporate Communications judith@trendlines.com